Thematics Asset Management Makes New Investment in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Thematics Asset Management bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 576 shares of the company’s stock, valued at approximately $46,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRCT. Signaturefd LLC raised its stake in shares of PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after buying an additional 145 shares during the last quarter. Naviter Wealth LLC lifted its stake in shares of PROCEPT BioRobotics by 6.0% in the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company’s stock valued at $249,000 after purchasing an additional 176 shares during the period. Amundi boosted its holdings in PROCEPT BioRobotics by 0.9% during the fourth quarter. Amundi now owns 20,143 shares of the company’s stock worth $1,742,000 after buying an additional 183 shares in the last quarter. Arizona State Retirement System grew its position in PROCEPT BioRobotics by 1.5% during the fourth quarter. Arizona State Retirement System now owns 14,285 shares of the company’s stock valued at $1,150,000 after buying an additional 218 shares during the period. Finally, KRS Capital Management LLC increased its holdings in PROCEPT BioRobotics by 0.5% in the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after buying an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 in the last ninety days. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock opened at $53.03 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The business has a 50 day simple moving average of $59.16 and a two-hundred day simple moving average of $74.66. The stock has a market capitalization of $2.91 billion, a P/E ratio of -27.19 and a beta of 1.09. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PRCT shares. Morgan Stanley dropped their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Truist Financial cut their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.43.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).